floxuridine has been researched along with Soft Tissue Neoplasms in 5 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
Soft Tissue Neoplasms: Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of the combination treatment consisted of 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA) was investigated in 20 recurrent breast cancer patients." | 9.08 | [The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient]. ( Hayashi, K; Taniguchi, T; Toi, M; Tominaga, T, 1995) |
| "Outpatients with advanced and recurrent breast cancer were treated by a combination therapy of the following drugs: doxifluridine (5'-DFUR) orally administered at a dose of 1200 mg/day; cyclophosphamide (CPA) orally given at dose of 100 mg/day; and tamoxifen (TAM) orally given at dose of 20 mg daily." | 9.07 | [Combination therapy of doxifluridine (5'-DFUR) + cyclophosphamide (CPA) + tamoxifen (TAM) for advanced or recurrent breast cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs]. ( Irie, K; Kawahara, T; Okumura, T; Ota, J; Sakai, K; Shimoyama, T; Taguchi, T; Terasawa, T; Yamamoto, M; Yasutake, K, 1992) |
| "A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer." | 7.67 | [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985) |
| "The effect of the combination treatment consisted of 5'-deoxy-5-fluorouridine (5'-DFUR) and medroxyprogesterone acetate (MPA) was investigated in 20 recurrent breast cancer patients." | 5.08 | [The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient]. ( Hayashi, K; Taniguchi, T; Toi, M; Tominaga, T, 1995) |
| "Outpatients with advanced and recurrent breast cancer were treated by a combination therapy of the following drugs: doxifluridine (5'-DFUR) orally administered at a dose of 1200 mg/day; cyclophosphamide (CPA) orally given at dose of 100 mg/day; and tamoxifen (TAM) orally given at dose of 20 mg daily." | 5.07 | [Combination therapy of doxifluridine (5'-DFUR) + cyclophosphamide (CPA) + tamoxifen (TAM) for advanced or recurrent breast cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs]. ( Irie, K; Kawahara, T; Okumura, T; Ota, J; Sakai, K; Shimoyama, T; Taguchi, T; Terasawa, T; Yamamoto, M; Yasutake, K, 1992) |
| "A comparative study was performed to evaluate the efficacy and safety of 5'-DFUR and tegafur in recurrent breast cancer." | 3.67 | [A comparative study of 5'-DFUR and tegafur in recurrent breast cancer]. ( Abe, O; Ogawa, N; Taguchi, T; Terasawa, T; Tominaga, T; Yoshida, Y, 1985) |
| "There were seven malignant fibrous histiocytomas, four liposarcomas, two fibrosarcomas, one leiomyosarcoma, and one rhabdomyosarcoma; 73% were grade III." | 1.28 | Intraarterial chemotherapy with limb-sparing resection of large soft-tissue sarcomas of the extremities. ( Bonn, J; Gardiner, GA; Lackman, RD; Shapiro, MJ; Soulen, MC; Sullivan, KL; Weiss, AJ; Weissmann, JR, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Toi, M | 1 |
| Taniguchi, T | 1 |
| Hayashi, K | 1 |
| Tominaga, T | 2 |
| Soulen, MC | 1 |
| Weissmann, JR | 1 |
| Sullivan, KL | 1 |
| Lackman, RD | 1 |
| Shapiro, MJ | 1 |
| Bonn, J | 1 |
| Weiss, AJ | 1 |
| Gardiner, GA | 1 |
| Ota, J | 1 |
| Taguchi, T | 2 |
| Sakai, K | 1 |
| Irie, K | 1 |
| Terasawa, T | 2 |
| Shimoyama, T | 1 |
| Kawahara, T | 2 |
| Okumura, T | 1 |
| Yamamoto, M | 1 |
| Yasutake, K | 1 |
| Takatsuka, Y | 1 |
| Katoh, T | 1 |
| Tsumura, I | 1 |
| Kobayakawa, K | 1 |
| Abe, O | 1 |
| Yoshida, Y | 1 |
| Ogawa, N | 1 |
2 trials available for floxuridine and Soft Tissue Neoplasms
| Article | Year |
|---|---|
[The effect of combination treatment consisted of 5'-deoxy-5-fluorouridine and medroxyprogesterone acetate for recurrent breast cancer patient].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; B | 1995 |
[Combination therapy of doxifluridine (5'-DFUR) + cyclophosphamide (CPA) + tamoxifen (TAM) for advanced or recurrent breast cancer. Joint Research Group in the Osaka Area for Combination Therapy of 5'-DFUR with Other Drugs].
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1992 |
3 other studies available for floxuridine and Soft Tissue Neoplasms
| Article | Year |
|---|---|
Intraarterial chemotherapy with limb-sparing resection of large soft-tissue sarcomas of the extremities.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Combined Modality Therapy; D | 1992 |
[Successful treatment of disseminated breast cancer with combination therapy of 5'-deoxy-5'-fluorouridine (5'-DFUR), medroxyprogesterone acetate (MPA) and cyclophosphamide (CPA)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Papillary; Cyclophospha | 1992 |
[A comparative study of 5'-DFUR and tegafur in recurrent breast cancer].
Topics: Administration, Oral; Adult; Aged; Anorexia; Antineoplastic Agents; Breast Neoplasms; Capsules; Diar | 1985 |